Human Polyomaviruses and Incidence of Cutaneous Squamous Cell Carcinoma in the New Hampshire Skin Cancer Study by Gossai, Anala et al.
Dartmouth College
Dartmouth Digital Commons
Open Dartmouth: Faculty Open Access Articles
1-25-2016
Human Polyomaviruses and Incidence of
Cutaneous Squamous Cell Carcinoma in the New
Hampshire Skin Cancer Study
Anala Gossai
Dartmouth College
Tim Waterboer
German Cancer Research Center (DKFZ)
Anne G. Hoen
Dartmouth College
Shohreh F. Farzan
Dartmouth College
Heather Nelson
University of Minnesota - Twin Cities
See next page for additional authors
Follow this and additional works at: https://digitalcommons.dartmouth.edu/facoa
Part of the Oncology Commons
This Article is brought to you for free and open access by Dartmouth Digital Commons. It has been accepted for inclusion in Open Dartmouth: Faculty
Open Access Articles by an authorized administrator of Dartmouth Digital Commons. For more information, please contact
dartmouthdigitalcommons@groups.dartmouth.edu.
Recommended Citation
Gossai, Anala; Waterboer, Tim; Hoen, Anne G.; Farzan, Shohreh F.; Nelson, Heather; Michel, Angelika; Willhauck-Fleckenstein,
Martina; Christensen, Brock; Perry, Ann; Pawlita, Michael; and Karagas, Margaret, "Human Polyomaviruses and Incidence of
Cutaneous Squamous Cell Carcinoma in the New Hampshire Skin Cancer Study" (2016). Open Dartmouth: Faculty Open Access
Articles. 684.
https://digitalcommons.dartmouth.edu/facoa/684
Authors
Anala Gossai, Tim Waterboer, Anne G. Hoen, Shohreh F. Farzan, Heather Nelson, Angelika Michel, Martina
Willhauck-Fleckenstein, Brock Christensen, Ann Perry, Michael Pawlita, and Margaret Karagas
This article is available at Dartmouth Digital Commons: https://digitalcommons.dartmouth.edu/facoa/684
1239
Introduction
Cutaneous squamous cell carcinoma (SCC) is a keratino-
cyte cancer (KC), with increasing incidence rates reported 
in the United States [1–4], Australia [5, 6], and Europe 
[7, 8]. Estimates of up to 420,000 individuals in the United 
States were diagnosed with incident SCC in 2012, and 
8800 SCC patients died from this malignancy [2]. 
Established risk factors include elderly age [1, 4, 9] and 
ultraviolet light [10, 11], but environmental exposure to 
ionizing radiation [12, 13], arsenic [14–17], and polycyclic 
aromatic hydrocarbons [18, 19] further increases the risk 
of SCC. Inherited traits such as skin pigmentation [20, 
21] and genetic defects in the ability to correct DNA 
photolesions (e.g., xeroderma pigmentosum) [22–24] also 
contribute to risk. While the prognosis is generally favora-
ble, metastases can occur; and the aging population, as 
well as disfigurement and morbidity resulting from SCC, 
makes this malignancy an important public health concern 
and under-recognized health burden.
Immunocompromised persons (e.g., organ transplant 
recipients, and those given immunosuppressant medica-
tions) carry a higher risk of SCC [1, 4, 25–28], raising 
the possibility of a viral etiology. However, the detection 
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Abstract
Squamous cell carcinoma (SCC) of the skin is a malignancy arising from epi-
thelial keratinocytes. Experimental and epidemiologic evidence raise the possibility 
that human polyomaviruses (PyV) may be associated with the occurrence of 
SCC. To investigate whether the risk for SCC was associated with PyV infection, 
seropositivity to 10 PyV types was assessed following diagnosis in a population- 
based case–control study conducted in the United States. A total of 253 SCC 
cases and 460 age group and gender- matched controls were included. Antibody 
response against each PyV was measured using a multiplex serology- based glu-
tathione S- transferase capture assay of recombinantly expressed VP1 capsid 
proteins. Odds ratios (OR) for SCC associated with seropositivity to each PyV 
type were estimated using logistic regression, with adjustment for potentially 
confounding factors. SCC cases were seropositive for a greater number of PyVs 
than controls (P = 0.049). Those who were JC seropositive had increased odds 
of SCC when compared to those who were JC seronegative (OR = 1.37, 95% 
CI: 0.98–1.90), with an increasing trend in SCC risk with increasing quartiles 
of seroreactivity (P for trend = 0.04). There were no clear associations between 
SCC risk and serostatus for other PyV types. This study provides limited evi-
dence that infection with certain PyVs may be related to the occurrence of SCC 
in the general population of the United States.
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of viral sequences in tumors can reflect either a causal 
or bystander role [29, 30]. Thus far, genus β human 
papillomaviruses (HPV) [31, 32] have been associated with 
an increased risk of SCC, but a causal relationship has 
not yet been established in the general population [33].
A potential etiologic role for polyomaviruses (PyV) in 
cancer has been investigated, and a rapidly expanding 
number of viral types are being identified in the family 
Polyomaviridae (reviewed in DeCaprio & Garcea, 2013 
[34]). PyVs are DNA viruses with an icosahedral capsid 
~45 nm in diameter containing a circular double- stranded 
genome [35, 36] that encodes capsid proteins (VP1, VP2, 
and VP3), as well as small and large T antigens (TAg) 
[35]. In simian virus- 40 (SV40), a PyV naturally infecting 
Asian macaques [37, 38], the large TAg possesses tumo-
rigenic properties, including the ability to bind and thereby 
inactivate tumor suppressor proteins Rb [39] and p53, 
[40] stimulating host cell cycle [35].
While the ability of PyVs to cause tumors in vitro and 
in experimental systems is undisputed, their role in human 
malignancies—and specifically KCs—is just beginning to 
emerge. Multiple human PyVs show evidence of skin tropism, 
including Merkel cell polyomavirus (MCV), Trichodysplasia 
spinulosa–associated polyomavirus (TSV), and human poly-
omaviruses 6 and 7 (HPyV6 and HPyV7) [36]. MCV was 
initially discovered in Merkel cell carcinoma (MCC) of the 
skin [41], and integration of the viral genome in MCC 
tumors [42] with potentially carcinogenic mutations in the 
large TAg [43] supported a causal role for MCV in MCC 
development. Recently, a clinic- based case–control study from 
Florida, USA, found an increased SCC risk associated with 
antibodies against MCV measured following diagnosis, and 
the association was stronger among those with tumors con-
taining MCV viral sequences [44]. Conversely, a case–control 
study conducted within organ transplant recipients found 
no evidence of an association between SCC development 
following transplant surgery and the seroprevalence of numer-
ous PyV types prior to transplantation [45]. Further, a large 
prospective Swedish study found no association between SCC 
and JC seropositivity assessed prior to diagnosis [46].
Limited epidemiologic research exists on the role of 
PyV infections (apart from MCV) in SCC carcinogenesis. 
We therefore sought to investigate the potential associa-
tion between PyVs and SCC by performing a compre-
hensive serologic analysis of the frequency of antibodies 
to the first 10 identified human PyVs: BK virus [47]; JC 
virus [48]; Karolinska Institute polyomavirus (KI) [49]; 
Washington University polyomavirus (WU) [50]; MCV 
[41]; HPyV6 and HPyV7 [51]; TSV [52]; human poly-
omavirus 9 (HPyV9) [53]; and Malawi/human polyoma-
virus 10 (HPyV10) [54] in plasma samples collected as 
part of a large, population- based case–control study con-
ducted in New Hampshire, USA.
Materials and Methods
Study population
The New Hampshire Skin Cancer Study population and 
methods have been described in detail elsewhere (epide-
miologic study design described in Karagas et al., 1998 
[55]) [32, 56, 57]. Briefly, histologically-confirmed, incident 
SCC cases were identified through active surveillance of 
dermatology and pathology laboratories throughout New 
Hampshire, USA. We selected all identified SCC cases 
diagnosed between July 1993 and June 1995, during the 
first enrollment phase of this large, population- based 
case–control study. Controls were selected from lists of 
New Hampshire residents obtained from the New 
Hampshire Department of Transportation (<65 years) and 
Medicare enrollment lists (≥65 years), and frequency-
matched to the age (25–34, 35–44, 45–54, 55–64, 65–69, 
and 70–74 years) and gender distribution of cases. For 
the purpose of the interview, controls were randomly 
assigned a reference date that matched a case’s diagnosis 
date. To be eligible, participants were required to be resi-
dents of New Hampshire, aged 25–74 years at time of 
diagnosis, speak English, and have a listed telephone 
number. We excluded participants with squamous cell or 
basal cell carcinomas on genital sites.
Study participants completed an extensive, structured 
interview, usually in their homes. Personal interviews were 
conducted to obtain sociodemographic information (e.g., 
level of education), lifestyle factors (e.g., cigarette smok-
ing), sunlight- related characteristics (e.g., response to first 
exposure in summer to 1 h of sunlight, number of severe 
sunburns, and skin color), and medical history (e.g., prior 
history of skin cancer, use of oral glucocorticoids for 
1 month or longer, and organ transplant status). Data 
on the primary tumor(s) (e.g., SCC anatomical location) 
were collected from a medical records review. Tumors 
diagnosed as a recurrence of a previously treated tumor, 
and those appearing contiguous with a scar from a previ-
ously excised skin cancer, were not considered a new 
primary SCC and thus were excluded. All participants 
provided informed consent in accordance with the 
Committee for the Protection of Human Subjects at 
Dartmouth College.
Human polyomavirus serology
As part of the New Hampshire Skin Cancer Study, we 
requested a blood sample from all participants for use 
in future research [55]. We collected venous blood samples 
of 20–30 mL in heparinized tubes following SCC diagnosis 
(as described in [32, 56]). Blood was separated by cen-
trifugation at 2500g for 20 min at 4°C, and each 
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component (plasma, red blood cells, and buffy coat) was 
labeled and stored separately at −80°C until analysis. 
Specimen label did not reveal the case–control status of 
the study participant. Samples were shipped to the German 
Cancer Research Center (DKFZ; Heidelberg, Germany) 
on dry ice for analysis.
Plasma samples were assayed for antibodies against the 
immunodominant VP1 capsid protein [58] of 10 human 
PyVs (BK, JC, KI, WU, MCV isolate 344, HPyV6, HPyV7, 
TSV, HPyV9, and HPyV10). Plasma samples were also 
tested for antibodies against the TAg of selected PyV types 
(large TAg for BK, JC, MCV, HPyV6, HPyV7, TSV, 
HPyV10, and small TAg for MCV). In our prior study, 
we did not find strong positive correlations or evidence 
of cross-reactivity between the VP1 capsid proteins of 
most PyV types (data not shown), suggesting that risk 
estimates obtained during analysis would be specific to 
that PyV type [59]. However, the strong positive correla-
tions between TAg seroreactivities from various PyVs 
suggestive of assay cross-reactivity (Fig. S1), and the small 
number of participants TAg seropositive, resulted in the 
exclusion of TAg serostatus from the presented analyses. 
The multiplex antibody detection approach was based on 
a glutathione S- transferase (GST) capture enzyme- linked 
immunosorbent assay (ELISA) method in combination 
with fluorescent bead technology (Luminex Corp., Austin, 
Texas) [60, 61]. Antigen preparation and techniques used 
for PyVs [44, 58, 62] closely follow methods applied to 
HPVs as described previously [60, 63].
Seroreactivity against PyV VP1 proteins was expressed 
as the median fluorescence intensity (MFI) of 100+ beads 
of the same internal color [61]. MFI values reflect anti-
body affinity, titer, and reactivity determined by dilution 
series [64]. Standard cut points to define seropositivity 
were chosen for each PyV by visual inspection of frequency 
distribution curves (percentile plots) for the inflection 
points of all sera tested, as done in prior studies [56, 62, 
63, 65]. The standard cutoff value for VP1 was 250 MFI 
units for all 10 PyVs (as used in Teras et al., 2014 [66] 
and Gossai et al., 2016 [59]). To evaluate the robustness 
of odds ratio (OR) estimates for SCC by PyV seropositiv-
ity, we used a sliding cut point between 50 and 450 MFI 
units, and also calculated cut points from controls using 
a method adapted from van der Meijden et al., 2013 [67] 
(Fig. S2). Given the stability of ORs to cut point defini-
tion, we ultimately used the standard cut points in all 
analyses.
Statistical analysis
Individual characteristics of SCC cases and controls were 
compared using the X2 test (for categorical variables, i.e., 
gender, education, smoking status, skin color, skin sun 
sensitivity, number of sunburns, prior KC, glucocorticoid 
use) or Fisher’s exact test (for categorical variables with 
small strata, i.e., transplant recipients), and Wilcoxon rank 
sum test (for continuous variables, i.e., age, mean number 
of PyVs seropositive). Among controls, we previously 
published the seroprevalence of each PyV type, and tested 
the association between various individual characteristics 
in relation to PyV seropositivity; therefore, these analyses 
were not repeated in this study [59].
We used unconditional logistic regression to calculate 
the ORs and 95% confidence intervals (CI) for SCC by 
VP1 seropositivity compared to seronegativity for each 
PyV type, while adjusting for age group and gender (as 
used in the frequency matching). We also examined sero-
positivity for multiple PyV types (7–8 and 9–10 types 
positive compared with 1–6 types positive), and calculated 
a P for trend based on these categories and a continuous 
variable of the number of types seropositive. Quartiles of 
seroreactivity based on the control distributions of con-
tinuous MFI values were created for each PyV, and asso-
ciated with SCC by comparing the second, third, and 
fourth quartile to the first (lowest) quartile. Tests for 
trend were conducted by including an ordinal variable 
in the logistic model. In addition, we evaluated seroposi-
tivity for multiple cutaneous PyVs (i.e., MCV, HPyV6, 
HPyV7, and TSV), and whether seropositivity for all 4 
or ≤3 cutaneous PyVs, was associated with SCC risk.
Potentially confounding covariates included level of 
education, smoking status, eye color, hair color, skin color, 
skin sensitivity to the sun, number of lifetime painful 
sunburns, lifetime sun exposure, and the self- reported use 
of oral glucocorticoids for 1 month or longer. As none 
of these factors consistently produced a >10% change in 
OR [68] when individually placed in a logistic regression 
model including the frequency matching factors (age group 
and gender), our OR estimates were ultimately adjusted 
for only these factors.
We assessed the potential modifying effects of prolonged 
oral glucocorticoid use for reasons other than organ trans-
plantation, as PyVs have been related to skin conditions 
and cancers in immunosuppressed populations. In these 
stratified analyses, we classified participants as users if 
they reported taking glucocorticoids for 1 month or longer, 
and excluded those who reported having had an organ 
transplant. An association between SCC risk and sero-
positivity to multiple cutaneous β HPVs has been reported 
previously [31, 32]. Therefore, using published serologic 
data from the New Hampshire Skin Cancer Study [31, 
32] on 16 cutaneous β HPVs (specifically, 5, 8, 20, 24, 
36 (beta- 1); 9, 15, 17, 23, 38, 107 (beta- 2); 49, 75, 76 
(beta- 3); 92 (beta- 4); and 96 (beta- 5)), we stratified par-
ticipants by those with seropositivity to 0–1 or seropositivity 
to ≥2 β HPV types to assess possible effect modification 
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by concomitant β HPV infections. We further calculated 
separate ORs for SCC occurring exclusively on anatomical 
sites with chronic sunlight exposure (head or neck) and 
other body sites in comparison to controls.
As sensitivity analyses, we excluded participants with a 
history of organ transplantation (n = 7), restricted to 
participants with no previous skin cancers (neither a prior 
SCC nor BCC; n = 423 controls and 179 cases), and 
excluded participants with a concomitant basal cell car-
cinoma (n = 22 cases) to assess whether the OR estimates 
differed from those obtained for all participants. No 
appreciable change in results was detected (Fig. S3), and 
thus these individuals were included in the presented 
analyses. All statistical tests were two-sided and significance 
was assessed at the α = 0.05 level. Statistical analyses 
were performed in R version 3.0.1.
Results
Study population characteristics
Plasma samples for PyV serology were obtained from 253 
(86.3%) of the 293 interviewed SCC cases following diag-
nosis, and 460 (85.2%) of the 540 interviewed controls 
(excluding 1 control with an insufficient bead count during 
serologic analysis). No appreciable differences were noted 
in the characteristics of individuals for whom we did not 
obtain serology data (data not shown). Compared to 
controls, SCC cases were older, were of lighter skin color, 
had skin that tended to burn following sun exposure, 
reported a greater number of painful sunburns in their 
lifetime, were more likely to have had a prior KC (SCC 
and/or BCC), and were more likely to have had an organ 
transplant (Table 1).
Polyomaviruses and cutaneous squamous 
cell carcinoma
Seroprevalences ranged from 17.6% for HPyV9 to 99.1% 
for HPyV10 among controls, and from 22.9% for HPyV9 
to 98.8% for HPyV10 among cases (Fig. 1). All study 
participants were seropositive for at least one type of PyV, 
but cases (mean = 7.52, standard deviation = 1.40) were 
seropositive for a slightly greater number of PyVs than 
controls (mean = 7.30, standard deviation = 1.45; Wilcoxon 
rank sum test P = 0.049). However, we found no evidence 
of an increasing trend in SCC odds with increasing number 
of PyV types for which an individual tested seropositive, 
either using a categorical variable (P for trend = 0.42) 
or on a continuous scale (P = 0.32) (Table 2). Further, 
no association with SCC was observed for combined sero-
positivity to the known cutaneous PyVs (i.e., MCV, HPyV6, 
HPyV7, and TSV; Table S2).
Table 1. Selected characteristics of cutaneous squamous cell carcinoma 
(SCC) cases and controls from the New Hampshire Skin Cancer Study 
(n = 713).1
Variable SCC cases (n = 253), 
No. (%)
Controls (n = 460), 
No. (%)
Gender
Male 168 (66.4) 280 (60.9)
Female 85 (33.6) 180 (39.1)
Median age, SD (years) 68 (8.0) 65 (10.7)***
Education
Elementary to high or 
technical school
111 (43.9) 227 (49.3)
Any college 80 (31.6) 144 (31.1)
Graduate or professional 
school
61 (24.1) 89 (19.3)
Smoking status2
Never 79 (31.2) 146 (31.7)
Former 133 (52.6) 230 (50.0)
Current 40 (15.8) 84 (18.3)
Skin color
Light 213 (84.2) 279 (60.6)***
Medium 38 (15.0) 180 (39.1)
Skin sun sensitivity3
Severe sunburn with 
blistering
22 (8.7) 28 (6.1)***
Painful sunburn and 
then peeling
93 (36.8) 116 (25.2)
Mild sunburn with some 
tanning
111 (43.9) 234 (50.9)
Tan without sunburn 25 (9.9) 80 (17.4)
No. of lifetime painful sunburns4
0 66 (26.1) 147 (32.0)***
1–2 49 (19.4) 134 (29.1)
3+ 136 (53.8) 174 (37.8)
Prior keratinocyte cancer5
Yes 74 (29.2) 37 (8.0)***
No 179 (70.8) 423 (91.9)
Glucocorticoid use6
Yes 33 (13.0) 39 (8.5)
No 211 (83.4) 415 (90.2)
Transplant recipient
Yes 6 (2.4) 1 (0.2)**
No 246 (97.2) 458 (88.6)
*P < 0.05, **P < 0.01, ***P < 0.001. P values obtained from X2, Fisher’s 
exact, or Wilcoxon rank sum test (as appropriate) comparing sociode-
mographic and skin cancer risk factors between SCC cases and 
controls.
1Numbers may not sum to the overall total due to missing data. They 
were excluded from complete case analyses.
2Cigarette smoking status at 1 year prior to the reference or diagnosis 
date
3Sun sensitivity was defined as the skin reaction to 1 h of sun exposure 
the first time in the summer.
4Sunburns that caused pain for 2 or more days
5Prior keratinocyte cancer was defined as having had a previous squa-
mous cell, basal cell, or both squamous cell and basal cell carcinoma.
6Glucocorticoid use was defined as having used oral steroid or corticos-
teroid medications (e.g., cortisone or prednisone) for 1 month or longer.
1243© 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
Polyomavirus and Squamous Cell CarcinomaA. Gossai et al.
In an analysis of SCC associations with antibodies to 
specific capsid antigens from each PyV type (classified as 
a dichotomous variable), an elevated odds of SCC was 
observed with seropositivity to JC of borderline statistical 
significance (OR = 1.37, 95% CI: 0.98–1.90; Fig. 1), and 
a positive trend in SCC risk was associated with increas-
ing MFI quartiles of JC seroreactivity (P for trend = 0.04) 
(Table 3). A weakly positive association with SCC risk 
was observed for seropositivity to WU (OR = 2.04, 95% 
CI: 0.64–6.49) (Fig. 1), and a slightly inverse association 
with SCC risk was observed for seropositivity to HPyV10 
(OR = 0.72, 95% CI: 0.16–3.32), but neither estimates 
achieved statistical significance. There were no trends in 
SCC risk by MFI quartiles for any PyV type but JC (Table 
S1).
SCC was more strongly related with seropositivity to 
JC among those reporting oral glucocorticoid use for 
Figure 1. Odds ratios (95% confidence intervals as whiskers) for cutaneous squamous cell carcinoma (SCC) by seropositivity for each polyomavirus 
(PyV) type among 713 study participants from the New Hampshire Skin Cancer Study. The overall seroprevalences (%) and number of participants 
who were seropositive for each PyV are shown below the plot area separately for cases and controls.
Table 2. Odds ratios (95% confidence intervals) for cutaneous squa-
mous cell carcinoma (SCC) by number of polyomavirus (PyV) types sero-
positive among 713 study participants from the New Hampshire Skin 
Cancer Study.
No. of PyV types 
seropositive
Controls 
(n = 460),  
No. (%)
SCC cases (n = 253)
No. (%) OR (95% CI)1
1–6 129 (28.0) 60 (23.7) 1.00 (referent)
7–8 236 (51.3) 128 (50.6) 1.04 (0.71–1.53)
9–10 95 (20.6) 65 (25.7) 1.21 (0.76–1.91)
P for trend 0.42
Continuous 
[mean No. (SD)]
7.30 (1.45) 7.52 (1.40) 1.06 (0.95–1.18)
P 0.32
OR, odds ratio; CI, confidence interval; SD, standard deviation.
1Adjusted for age group and gender.
Table 3. Odds ratios (95% confidence intervals) for cutaneous squa-
mous cell carcinoma (SCC) by quartiles of JC polyomavirus (PyV) serore-
activity among 713 study participants from the New Hampshire Skin 
Cancer Study.
PyV  seroreactivity 
(MFI units)
Controls (n = 460), 
No. (%)
SCC cases (n = 253)
No. (%) OR (95% CI)1
JC
Quartile 1 115 (25.0) 51 (20.2) 1.00 (referent)
Quartile 2 115 (25.0) 43 (17.0) 0.79 (0.48–1.30)
Quartile 3 115 (25.0) 74 (29.2) 1.27 (0.80–1.99)
Quartile 4 115 (25.0) 85 (33.6) 1.41 (0.90–2.20)
P for trend 0.04
OR, odds ratio; CI, confidence interval.
1Adjusted for age group and gender.
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1 month or longer (OR = 1.88, 95% CI: 0.61–5.76) than 
those without a history of prolonged glucocorticoid use 
(OR = 1.37, 95% CI: 0.96–1.96)—albeit with limited sta-
tistical power (P for interaction = 0.50; Fig. S4). When 
excluding glucocorticoid users, the positive association 
between SCC risk and HPyV9 seropositivity was strength-
ened (OR = 1.49, 95% CI: 0.99–2.24). Interestingly, a 
weakly positive association with SCC risk was found for 
HPyV10 seropositivity among those seropositive for <2 
β HPV types (OR = 1.45, 95% CI: 0.15–14.37), although 
with wide confidence intervals. We did not find any notable 
differences for the other PyVs according to glucocorticoid 
use, anatomical site of the SCC tumor, or seropositivity 
to β HPVs, in stratified analyses.
Discussion
We measured antibodies against the first 10 discovered 
human PyVs in a large, population- based case–control 
study to investigate the relation between multiple PyVs 
and SCC incidence. No clear associations were observed 
for most PyV types and SCC risk. However, we observed 
an intriguing elevated odds ratio for SCC associated with 
JC seropositivity that approached statistical significance, 
and a trend in risk by quartiles of JC seroreactivity. While 
no clear associations were detected, we had limited sta-
tistical power for many of these analyses due to the high 
PyV seroprevalence.
Several epidemiologic studies have raised the possibility 
of an oncogenic role for PyV infection in SCC develop-
ment. Among 173 SCC cases and 300 controls in a clinic- 
based case–control study conducted in Florida, USA, MCV 
seropositivity was related to an increased risk for SCC 
(OR = 1.58, 95% CI: 0.96–2.60), and the association was 
strongest among those with tumors containing MCV DNA 
(OR = 2.49, 95% CI: 1.03–6.04) [44]. We did not observe 
evidence of an association with MCV seropositivity. An 
association of a similar magnitude with JC seropositivity 
was also observed in the Florida study (OR = 1.40, 95% 
CI: 0.89–2.20). However, unlike our study, there was no 
trend by quartiles of JC seroreactivity (P for trend = 0.44) 
[44].
In our case–control study design, we are unable to 
address the issue of ‘reverse causality’ common to studies 
aiming to elucidate the etiology of KC at or following 
diagnosis. Namely, it is possible that antibodies measured 
at the time of SCC diagnosis do not accurately reflect 
antibodies that would have been circulating in the early 
stages of carcinogenesis. Indeed, a large, prospective, 
Swedish study which drew upon samples donated to a 
biobank and cancer registry data found no association 
between SCC (OR = 1.0, 95% CI: 0.8–1.4) or BCC 
(OR = 0.9, 95% CI: 0.8–1.1) and prediagnostic JC 
seropositivity, with blood samples collected at least 1 month 
prior to diagnosis [46]. However, the primary hypothesis 
of the Swedish study was an association between HPV 
and SCC or BCC, and thus used a multiplex assay opti-
mized for the detection of antibodies against various HPV 
types, with JC included as a specificity control [46]. A 
discrepancy in results may be attributed to both differing 
populations and assay optimization for human PyV types. 
Thus, further prospective data that include repeated meas-
urements over time from each participant are needed.
Increased incidence of cancers in immunosuppressed 
patients, such as skin cancers [27], suggests a possible 
viral etiology that may be attributed to impaired immune 
surveillance of infections with oncogenic potential. 
Moreover, immune suppression could lead to viral reac-
tivation and higher levels of antibodies, thus confounding 
any observed relationship between PyVs and SCC. A greater 
than expected proportion of transplant recipients are sero-
positive for KI and WU [69, 70], and MCV sequences 
are also more frequently found in the skin tumors of 
immunocompromised patients than those from immuno-
competent individuals [71]. TSV seroprevalence is likewise 
higher in renal transplant patients when compared to 
healthy participants [72], and has been causally linked to 
a rare disease of abnormal maturation of the hair follicles 
characterized by spiny lesions on the skin [73, 74]. HPyV9 
was first isolated from a kidney transplant recipient [53] 
and has been found at higher seroprevalence in immu-
nocompromised patients [75]. HPyV10 was isolated from 
a patient with warts, hypogammaglobulinemia, infections, 
and myelokathexis (WHIM) syndrome [54], an inherited 
immune deficiency with increased susceptibility to HPV- 
induced warts and cancers [76, 77]. BK and JC are known 
to reactivate under conditions of immunosuppression [78, 
79]. Indeed, JC seropositivity has been used as an indicator 
of immune status in prior studies [44]. In a small, nested 
case–control study among transplant recipients, no excess 
risks for SCC following organ transplantation were found 
with antibody levels against PyVs (specifically, JC, KI, WU, 
MCV, HPyV6, and HPyV7) in serum drawn immediately 
prior to surgery (n = 149 SCC cases and 290 controls) 
[45]. We observed increased odds of SCC associated with 
increasing JC antibody levels, which may reflect the detec-
tion of JC reactivation arising from immune dysregulation 
associated with skin cancer. Therefore, our findings of an 
association between JC serostatus and SCC could represent 
the predisposing role of immunodeficiency, rather than 
the virus itself. With limited statistical power, there was 
weak evidence that the association we found between SCC 
and JC seropositivity may be slightly stronger among those 
with prolonged oral glucocorticoid use, raising the pos-
sibility of effect modification rather than confounding by 
immunosuppression. However, further studies are needed.
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MCV, TSV, HPyV6, and HPyV7 show evidence of skin 
tropism [36], yet we found no association with SCC risk. 
We could not assay for the presence of PyV DNA within 
SCC tumor tissues, which is a more direct indication of 
a potential association between PyVs and SCC. In the 
Florida study, MCV TAg DNA was isolated from ~40% 
of SCC tumors from patients, but they did not find BK, 
JC, KI, or WU TAg DNA sequences within SCC tumors 
[44]. Other small studies have failed to detect DNA from 
JC in skin swabs [80] or skin biopsies from normal skin 
[81], common warts, Bowen’s disease [82], BCC [83], 
SCC [81, 83], melanoma [81, 84], or cutaneous B- cell 
lymphomas [85]. However, JC TAg sequences were detected 
in Kaposi’s sarcoma skin lesions, and has been amplified 
from 16% of healthy skin tissues [86], suggesting that 
these viruses can inhabit the skin even without being 
skin tropic [36] or the skin acting as a suitable host for 
viral propagation [87]. A potential etiologic role of JC 
in the absence of JC DNA within tumors remains unex-
plained and warrants additional study.
All human PyVs discovered thus far encode proteins 
that allow them to act as oncoviruses. Indeed, the virus’ 
name is derived from the Greek poly meaning ‘many’ and 
oma referring to their induction of tumors in murine 
models [88]. Truncating mutations in the large TAg of 
integrated MCV are characteristic of MCC tumors, with 
domains required for Rb- induced cell transformation pre-
served, while those for viral replication and p53 binding 
[43] are eliminated resulting in no interaction with p53 
[89], thereby enhancing the likelihood of cell survival. 
Truncating mutations of the TAg have not been described 
in other human PyVs. Consequent to its transforming 
potential, the large TAg has been considered the main 
oncoprotein in PyVs [36]. The small TAg and agnoprotein 
expressed by some viruses also exhibit oncogenic properties 
[36]. The late regions of BK and JC encode an agnoprotein 
which exerts a tumorigenic effect through cell  cycle dys-
regulation, interference with DNA repair processes, and 
increased chromosome instability [90, 91]. Similar to SV40 
[92], BK, JC, and MCV encode a miRNA that downregu-
lates large TAg expression, which may allow the virus to 
escape the immune system [93]. Thus, there is some evi-
dence for a putative mechanistic role for PyVs in human 
carcinogenesis, although further research is needed.
It has been theorized that PyVs may serve as cofactors 
for oncoviruses by acting on common tumorigenic targets, 
perturbing the cell cycle, assisting with immune evasion, 
or transactivating the promoters of co- infecting viruses—
although evidence of such an interaction is lacking [29]. 
Interactions between PyVs and other viruses have been 
documented, such as the in vitro cooperation between JC 
and the HIV- 1 regulatory protein, Tat, that enhances JC 
transcription in glial cells [94, 95]. Additionally, 
interactive effects between a murine PyV strain with 
Moloney murine leukemia virus have been shown to result 
in stunted growth only in co- infected animals, possibly 
through a proinflammatory cytokine pathway [96]. In our 
study, we were only able to assess concomitant seroposi-
tivity to β HPVs, and did not detect any consistent inter-
actions with PyV types and SCC risk.
Strengths and limitations
A strength of our study was the large number of histo-
logically confirmed cases of incident invasive SCC identified 
through active population- based surveillance, along with 
controls derived from the general US population. This 
type of study design decreases the opportunity for selec-
tion bias, and is more generalizable than clinic- or hospital- 
based case–control studies. Still, the possibility of selection 
bias and residual confounding cannot be excluded, and 
the generalizability to non- white populations is limited 
due to the study’s location in an almost exclusively white 
US population. The use of multiplex serology to com-
prehensively measure a wide range of human PyVs was 
an additional study strength. The GST capture of recom-
binantly expressed VP1 capsid proteins has been found 
to be a reliable technique to assess PyV seroreactivity and 
has been used as a marker of PyV infection in prior 
studies [44, 58, 62]. Our blood samples were collected 
following the skin cancer diagnosis, and thus PyV infec-
tion may have occurred during or following tumor devel-
opment, and the influence of disease state on susceptibility 
to PyV infection and immune response cannot be disen-
tangled from these data. We are unable to assess tempo-
rality or reverse causality, so the direction of any observed 
associations cannot be determined. PyV seropositivity does 
not necessarily correspond to the presence of PyV DNA 
in tumor tissues and seroreactivity is an indirect measure 
of infection. However, MCV viral load and antibody titer 
have been shown to have a strong positive monotonic 
correlation [97], with higher MFI values corresponding 
to MCV DNA- positive SCC tumor tissues [44]. Lastly, 
given the high seroprevalence of PyVs in the study popu-
lation, power to detect differences in SCC risk for some 
PyVs was limited.
Conclusions
In this population- based case–control study, we examined 
the association between the first 10 discovered human 
PyVs and incidence of SCC using multiplex serology. Our 
findings, though limited, provide some support for the 
possibility that specific PyV types may play a role in the 
occurrence of SCC in the US population, but not PyV 
seropositivity in general.
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Supporting Information
Additional supporting information may be found in the 
online version of this article:
Table S1. Odds ratios (95% confidence intervals) for 
cutaneous squamous cell carcinoma (SCC) by quartiles 
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of polyomavirus (PyV) seroreactivity among 713 study 
participants from the New Hampshire Skin Cancer Study.
Table S2. Odds ratios (95% confidence intervals) for 
cutaneous squamous cell carcinoma (SCC) by seropositivity 
for all cutaneous polyomaviruses (PyV), and by number 
of cutaneous PyV types seropositive, among 713 study 
participants from the New Hampshire Skin Cancer Study.
Figure S1. Spearman rank correlation coefficients, ρ, between 
the median fluorescence intensity (MFI) values against each 
human polyomavirus (PyV) VP1 or T antigen (TAg) among 
460 controls from the New Hampshire Skin Cancer Study, 
where *P<0.05, **P<0.01, ***P<0.001. Not all PyV TAgs 
were assayed, and MCV large TAg was assayed using the 
entire protein as well as with two fragments (exon 1 and 
exon 2) of the full length large TAg. The red triangle 
emphasizes the strong correlations between PyV TAgs.
Figure S2. Robustness of odds ratio (OR) estimates for 
cutaneous squamous cell carcinoma (SCC) by seropositivity 
for each polyomavirus (PyV) type among 713 study par-
ticipants from the New Hampshire Skin Cancer Study, 
following adjustment for age group and gender. The cut 
points were varied from 50 to 450 median fluorescence 
intensity (MFI) units (x axis), and the resulting ORs were 
calculated using the new cutoffs (y axis). The red dots 
show the ORs using the recommended cutoff of 250 MFI 
units. The blue dots denote the cut points calculated using 
a frequency distribution analysis described in van der 
Meijden et al, 2013 (67). OR estimates for HPyV10 could 
not be accurately computed due to the viruses’ high sero-
prevalence. The gray bands are the 95% confidence intervals 
(CI) about each OR.
Figure S3. Plot of odds ratios (95% confidence intervals 
as whiskers) for cutaneous squamous cell carcinoma (SCC) 
by seropositivity for each polyomavirus (PyV) type among 
study participants from the New Hampshire Skin Cancer 
Study, when excluding participants with a history of organ 
transplantation (“organ”, n = 1 control and 6 cases), 
restricting to participants with no previous skin cancers 
(“NMSC”, n = 423 controls and 179 cases), and exclud-
ing participants with a concomitant basal cell carcinoma 
(“BCC”, n = 22 cases), following adjustment for age 
group and gender. “Main” refers to unstratified risk esti-
mates presented in Figure 1. The dashed line represents 
an OR=1.
Figure S4. Plot of odds ratios (95% confidence intervals 
as whiskers) for cutaneous squamous cell carcinoma 
(SCC) by seropositivity for each polyomavirus (PyV) 
type among study participants from the New Hampshire 
Skin Cancer Study, when stratified by oral glucocorticoid 
use for 1 month or longer (“yes” refers to use (n = 39 
controls and 33 cases) and “no” to nonuse (n = 415 
controls and 211 cases); as people with a history of 
glucocorticoid use may also have undergone organ trans-
plantation, we restricted the analysis to those who were 
not organ transplant recipients), β HPV seropositivity 
(“≥2” (n = 125 controls and 82 cases) and “<2” (n = 335 
controls and 171 cases) refers to number of β HPV 
seropositive), and SCC location (“head” (n = 146 cases) 
refers to SCC located on the head or neck, and “other” 
(n = 97 cases) refers to SCC located on other body 
parts), following adjustment for age group and gender. 
“Main” refers to unstratified risk estimates presented in 
Figure 1. OR and 95% CI were not computed for strata 
in which all participants were seropositive for the PyV 
of interest (represented by a solid vertical black line). 
The dashed line represents an OR=1.
